The Type and the Position of HNF1A Mutation Modulate Age at Diagnosis of Diabetes in Patients with Maturity-Onset Diabetes of the Young (MODY)-3

TitreThe Type and the Position of HNF1A Mutation Modulate Age at Diagnosis of Diabetes in Patients with Maturity-Onset Diabetes of the Young (MODY)-3
Type de publicationArticle de revue
AuteurBellanné-Chantelot, Christine, Carette, Claire, Riveline, Jean-Pierre, Valéro, René, Gautier, Jean-François, Larger, Etienne, Reznik, Yves, Ducluzeau-Fieloux, Pierre-Henri , Sola-Gazagnes, Agnès, Hartemann-Heurtier, Agnès, Lecomte, Pierre, Chaillous, Lucy, Laloi-Michelin, Marie, Wilhem, Jean-Marie, Cuny, Pierre, Duron, Françoise, Guerci, Bruno, Jeandidier, Nathalie, Mosnier-Pudar, Helen, Assayag, Michel, Dubois-Laforgue, Danièle, Velho, Gilberto, Timsit, José
EditeurAmerican Diabetes Association
TypeArticle scientifique dans une revue à comité de lecture
DateFeb 2008
Pagination503 - 508
Titre de la revueDiabetes
ISSN0012-1797, 1939-327X
Mots-cléshepatocyte nuclear factor 1-α MODY, HNF1A, maturity-onset diabetes of the young
Résumé en anglais

OBJECTIVE—The clinical expression of maturity-onset diabetes of the young (MODY)-3 is highly variable. This may be due to environmental and/or genetic factors, including molecular characteristics of the hepatocyte nuclear factor 1-α (HNF1A) gene mutation.

RESEARCH DESIGN AND METHODS—We analyzed the mutations identified in 356 unrelated MODY3 patients, including 118 novel mutations, and searched for correlations between the genotype and age at diagnosis of diabetes.

RESULTS—Missense mutations prevailed in the dimerization and DNA-binding domains (74%), while truncating mutations were predominant in the transactivation domain (62%). The majority (83%) of the mutations were located in exons 1- 6, thus affecting the three HNF1A isoforms. Age at diagnosis of diabetes was lower in patients with truncating mutations than in those with missense mutations (18 vs. 22 years, P = 0.005). Missense mutations affecting the dimerization/DNA-binding domains were associated with a lower age at diagnosis than those affecting the transactivation domain (20 vs. 30 years, P = 10−4). Patients with missense mutations affecting the three isoforms were younger at diagnosis than those with missense mutations involving one or two isoforms (P = 0.03).

CONCLUSIONS—These data show that part of the variability of the clinical expression in MODY3 patients may be explained by the type and the location of HNF1A mutations. These findings should be considered in studies for the search of additional modifier genetic factors.

URL de la notice
Lien vers le document